DRMA on Nasdaq

Dermata Therapeutics, Inc.

American pharmaceutical preparations company based in San Diego. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerDRMA on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Diego, California1
  • Incorporated inDE2
  • Business address3525 Del Mar Heights Rd., #322, San Diego, Ca 921302
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Successfully draw awareness to our Tome skincare brand in preparation for the launch of our first commercial products. We recently announced the name of our new skincare brand, Tome, and are working on building the brand identity for our DTC skincare products, which will represent our core value of providing consumers with skincare products that come from nature but are scientifically proven to work.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45678-$7.8M in 2025+145% since 2020
-$15.0M-$10.0M-$5.0M02020: -$3.2M-$3.2M20202021: -$7.9M-$7.9M2021+148%2022: -$9.7M-$9.7M2022+23%2023: -$8.0M-$8.0M2023−17%2024: -$12.5M-$12.5M2024+56%2025: -$7.8M-$7.8M2025−38%
Net income45678-$7.6M in 2025+134% since 2020
-$15.0M-$10.0M-$5.0M02020: -$3.2M-$3.2M20202021: -$7.9M-$7.9M2021+144%2022: -$9.6M-$9.6M2022+22%2023: -$7.8M-$7.8M2023−19%2024: -$12.3M-$12.3M2024+58%2025: -$7.6M-$7.6M2025−38%
Fiscal year20192020202120222023202420252026
Research and development$1.6M4$3.5M5$5.7M6$4.1M7$8.2M8$2.9M8
Selling, general and admin$4.3M8$4.8M8
Operating expenses$9.7M6$8.0M7$12.5M8$7.8M8
Operating income-$3.2M4-$7.9M5-$9.7M6-$8.0M7-$12.5M8-$7.8M8
Interest$197.3K4$45.6K4
Income tax$04$05$06$07$07
Net income-$3.2M4-$7.9M5-$9.6M6-$7.8M7-$12.3M8-$7.6M8
Earnings per share-$1.694-$2.435-$13.926-$39.997-$80.328-$8.168
Earnings per share (diluted)-$39.997-$80.328-$8.168
Shares (weighted, basic)4.3M shares4153.0K shares8926.2K shares8
Shares (weighted, diluted)194.9K shares7153.0K shares8926.2K shares8

Compare Dermata Therapeutics, Inc. with another company

Leadership

Who has led Dermata Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Gerald T. Proehl2021–now

Chair

  1. Gerald T. Proehl2021–now

President

  1. Gerald T. Proehl2021–now

Chief financial officer

  1. Thomas Insley2021
  2. Hoose Kyri K. Van2021–now
2025
Board members and other officers (9)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerKyri K. Van Hoose named Jun 12, 2023 to Jan 7, 202625
  • Executive OfficerMaria J. Bedoya Toro Munera named Jun 12, 2023 to Jan 7, 202625

Timeline

  1. Aug 12, 2021New chief executive Gerald T. Proehl becomes CEO12

Filings

311 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 75 major events, 78 insider forms, 27 large holders, 5 private raises, 105 other. The latest 20:

  1. Oct 9, 2026S-3 EDGAR
  2. Aug 18, 20264 EDGAR
  3. Aug 18, 20264 EDGAR
  4. Aug 17, 20268-K EDGAR
  5. Aug 17, 202625-NSE EDGAR
  6. Aug 11, 202610-Q EDGAR
  7. Aug 11, 20268-K EDGAR
  8. Aug 5, 20268-K EDGAR
  9. Jun 16, 20264 EDGAR
  10. Jun 4, 2026S-8 EDGAR
  11. Jun 1, 2026SCHEDULE 13D EDGAR
  12. May 29, 2026EFFECT EDGAR
  13. May 29, 2026424B3 EDGAR
  14. May 27, 20268-K EDGAR
  15. May 27, 2026CORRESP EDGAR
  16. May 22, 2026S-3/A EDGAR
  17. May 13, 202610-Q EDGAR
  18. May 13, 20268-K EDGAR
  19. May 13, 2026SCHEDULE 13G/A EDGAR
  20. Apr 22, 2026SCHEDULE 13G/A EDGAR

The 311 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 2 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 16, 2026Scott Kathleen D.DirectorSale11$1.19$13Form 4
Feb 17, 2026Bedoya-Toro Munera Maria ESVP, Regulatory AffairsBuy1,000$1.27$1.3KForm 4
Nov 23, 2021PROEHL GERALD TPRESIDENT, CHAIRMAN, CEOBuy20,000$2.40$48.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 29, 2025Raised $4.1 million in a private offering of equity Form D: 14 investors so far Form D
  2. Jan 21, 2025Raised $2.5 million in a private offering of equity Form D: 8 investors so far Form D
  3. Sep 17, 2024Raised $3.5 million in a private offering of securities Form D: 1 investor so far Form D
  4. May 26, 2023Filed a private offering of securities Form D: 2 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Geode Capital Management, LLC20,203$26.1K0.0%−28,131
Welch & Forbes LLC20,000$25.8K0.0%No change
State Street Corp18,747$24.2K0.0%New
UBS Group AG16,796$21.7K0.0%−18,812
Susquehanna International Group, Llp15,989$20.6K0.0%New
XTX Topco Ltd14,787$19.1K0.0%New
Advisory Alpha, LLC10,000$12.9K0.0%New
Tower Research Capital LLC (TRC)3,860$5.0K0.0%+3,144
MCF Advisors LLC1,732$2.2K0.0%No change
Barclays PLC270$3480.0%New
SBI Securities Co., Ltd.101$1300.0%No change
Highline Wealth Partners LLC26$340.0%New
Morgan Stanley2$30.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31